Earnings results expected in 38 days
Summary
HO1 trading today lower at €55.5, a decrease of 0.89% from yesterday's close, completing a monthly increase of 9.9% or €5. Over the past 12 months, HO1 stock lost -20.14%.
HO1 is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Jul 28, 2025.
The stock of the company had never split.
The company's stock is traded on 10 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track HO1 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
HO1 Chart
Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights
Hologic (HOLX) concluded the recent trading session at $64.14, signifying a -1.6% move from its prior day's close.
Zacks | 2 days ago
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.
Zacks | 3 days ago
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
HOLX grapples with global headwinds, but growth in Diagnostics and Breast Health service lifts confidence.
Zacks | 1 week ago
Hologic Inc. Dividends
HO1 is not paying dividends to its shareholders.
Hologic Inc. Earnings
| 28 Jul 2025 (38 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
HO1 is not paying dividends to its shareholders.
| 28 Jul 2025 (38 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
Hologic Inc. (HO1) FAQ
What is the stock price today?
The current price is €55.50.
On which exchange is it traded?
Hologic Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is HO1.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
What is the earnings per share?
The EPS is 0.
When is the next earnings date?
The next earnings report will release on Jul 28, 2025.
Has Hologic Inc. ever had a stock split?
Hologic Inc. had 0 splits and the recent split was on Apr 03, 2008.
Hologic Inc. Profile
| Medical - Instruments & Supplies Industry | Healthcare Sector | Mr. Stephen P. MacMillan CEO | XSTU Exchange | US4364401012 ISIN |
| US Country | 7,063 Employees | - Last Dividend | 3 Apr 2008 Last Split | 21 Jun 1990 IPO Date |
Overview
Hologic, Inc. is a pioneering company focused on improving women’s health through early detection and treatment, leveraging advanced diagnostics, medical imaging systems, and surgical products. Founded in 1985 with its headquarters in Marlborough, Massachusetts, Hologic operates across four distinct segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its commitment to innovation and improving patient outcomes positions Hologic as a leader in the healthcare industry, ensuring it meets the diverse needs of healthcare providers and patients alike.
Products and Services
- Aptima Molecular Diagnostic Assays: These assays are designed to detect infectious microorganisms, playing a crucial role in the diagnosis and management of infectious diseases.
- Aptima Viral Load Assays: Specifies viral load measurements for Hepatitis B, Hepatitis C, HIV, and human cytomegalovirus, critical for monitoring and managing these infections.
- Aptima Bacterial Vaginosis and Candida Vaginitis Assays: Offer diagnosis solutions for vaginitis, improving patient care through accurate detection.
- Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 Assays: Enable the detection of SARS-CoV-2, the virus responsible for COVID-19, showcasing Hologic's capacity to respond to emergent health threats.
- ThinPrep System: Provides cytology applications, enhancing the accuracy of Pap tests for detecting cervical cancer at early stages.
- Rapid Fetal Fibronectin Test: Aids in assessing the risk of pre-term birth, offering critical information to healthcare providers for managing pregnancies.
- 3D Digital Mammography Systems: Revolutionizes breast cancer detection with advanced imaging technology, improving the early diagnosis of breast cancer.
- MyoSure Hysteroscopic Tissue Removal System: Allows for the minimally invasive removal of fibroids and polyps in the uterus, contributing to enhanced patient comfort and recovery.
- NovaSure Endometrial Ablation System: Provides treatment for abnormal uterine bleeding, offering an effective alternative to more invasive surgical procedures.
- Fluent Fluid Management System: Delivers liquid distention during hysteroscopic procedures, ensuring operational efficiency and safety.
- Acessa ProVu System: A minimally invasive solution for treating fibroids, demonstrating Hologic’s commitment to innovative treatment options.
- CoolSeal Portfolio: Features bipolar vessel sealing devices designed for surgical efficiency and patient safety during procedures.
- Horizon DXA: This dual-energy X-ray absorptiometry system is used for assessing bone density, aiding in the detection and treatment of osteoporosis.
- Fluoroscan Insight FD Mini C-arm: A compact imaging solution for orthopedic surgical procedures, enhancing the visualization needed for minimally invasive interventions.
Contact Information
Address: 250 Campus Drive
Phone: 508 263 2900
Website: https://www.hologic.com
2025 © Marketlog. All Rights Reserved.
